Praxis Precision Medicines (PRAX) Return on Capital Employed (2020 - 2026)
Praxis Precision Medicines (PRAX) posted quarterly Return on Capital Employed of 31.1% for Q1 2026, up 2168.0% year-over-year from 1.37% in Q1 2025, and up 42.08% quarter-over-quarter from 53.71% in Q4 2025.
Praxis Precision Medicines (PRAX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Praxis Precision Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 31.1% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2168.0% year-over-year to 31.1%; the TTM figure through Mar 2026 stood at 31.1% (up 2168.0% YoY), while the FY2025 annual figure was 50.13%, up 3059.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 31.1%, up from 53.71% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.1% in Q1 2026, with the low at 239.76% in Q1 2023.
- The 5-year median for Return on Capital Employed is 86.56% (2024), against an average of 108.61%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed tumbled 17258 bps in 2022, then jumped 15320 bps in 2024.
- Praxis Precision Medicines' Return on Capital Employed stood at 234.52% in 2022, then jumped by 34 bps to 154.89% in 2023, then jumped by 69 bps to 48.57% in 2024, then slipped by 11 bps to 53.71% in 2025, then jumped by 42 bps to 31.1% in 2026.
- Business Quant data shows PRAX's Return on Capital Employed at 31.1% in Q1 2026, 53.71% in Q4 2025, and 78.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.46 Bn | 131.61 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.04 Bn | 77.05 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.55 Bn | 59.36 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.56 Bn | 54.42 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.90 Bn | 36.80 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.69 Bn | 28.38 Bn | 992.69 Mn | 26.09% |
| 7 | Royalty Pharma | 27.45 Bn | 26.61 Bn | - | 7.88% |
| 8 | BioNTech SE | 27.40 Bn | 9.01 Bn | 668.28 Mn | -6.85% |
| 9 | Insmed | 26.70 Bn | 25.54 Bn | 358.27 Mn | -50.93% |
| 10 | Praxis Precision Medicines | 10.83 Bn | 10.07 Bn | - | -27.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.48% |
| Mar 31, 2026 | -31.10% |
| Dec 31, 2025 | -53.71% |
| Sep 30, 2025 | -78.85% |
| Jun 30, 2025 | -65.10% |
| Mar 31, 2025 | -52.79% |
| Dec 31, 2024 | -48.57% |
| Sep 30, 2024 | -41.44% |
| Jun 30, 2024 | -40.81% |
| Mar 31, 2024 | -86.56% |
| Dec 31, 2023 | -154.89% |
| Sep 30, 2023 | -135.52% |
| Jun 30, 2023 | -173.53% |
| Mar 31, 2023 | -239.76% |
| Dec 31, 2022 | -234.52% |
| Sep 30, 2022 | -179.05% |
| Jun 30, 2022 | -135.73% |
| Mar 31, 2022 | -94.50% |
| Dec 31, 2021 | -61.94% |
| Sep 30, 2021 | -42.77% |